Reverse Merger Considerations for Biotech Companies

This article is a guide discussing recent actions by the U.S. Securities and Exchange Commission (SEC) regarding reverse mergers, particularly for biotech companies. It outlines the challenges posed by new SEC rules that may affect special-purpose acquisition companies and de-SPAC transactions. The article details steps that companies should consider to avoid being classified as shell companies, which can jeopardize their ability to go public. It explains the definition of a shell company under SEC Rule 405 and the implications of recent SEC scrutiny on reverse mergers. The article also presents examples of recent biotech reverse mergers and highlights the potential consequences of the SEC's evolving position on shell companies. Companies are advised to evaluate their status carefully and consider engaging with the SEC early in the transaction process to mitigate risks associated with shell company classification. The guide emphasizes the need for strategic planning in light of these regulatory changes.